HCV and diabetes: towards a 'sustained' glycaemic improvement after treatment with DAAs?
Clin Microbiol Infect
.
2017 May;23(5):342-343.
doi: 10.1016/j.cmi.2016.09.021.
Epub 2016 Sep 29.
Authors
C Fabrizio
1
,
A Procopio
1
,
L Scudeller
2
,
R Dell'Acqua
1
,
G Bruno
1
,
E Milano
1
,
M Milella
1
,
A Saracino
3
,
G Angarano
1
Affiliations
1
Clinic of Infectious Diseases, University of Bari, Bari, Italy.
2
Scientific Direction, Clinical Epidemiology Unit, IRCCS San Matteo Foundation, Pavia, Italy.
3
Clinic of Infectious Diseases, University of Bari, Bari, Italy. Electronic address:
[email protected]
.
PMID:
27693659
DOI:
10.1016/j.cmi.2016.09.021
No abstract available
Publication types
Letter
Comment
MeSH terms
Antiviral Agents
Blood Glucose*
Diabetes Mellitus
Hepatitis C, Chronic*
Humans
Substances
Antiviral Agents
Blood Glucose